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EVOLUTION OF PRESCRIPTIONS AND DRUG COSTS IN
HYPERTENSION—RESULTS FROM A DATABASE FOLLOW-UP
STUDY
Berger W1,Annemans L2
1Merck KGaA, Darmstadt, Germany; 2Ghent University, HEDM, Meise,
Belgium
OBJECTIVE: To compare the evolution of persistence rates and
drug costs in patients whose antihypertensive therapy was
started with a low-dose combination therapy or with various
monotherapies in daily practice. METHODS: Patients in the
Thalès database in France, whose therapy was started with 1) a
low-dose combination of bisoprolol and hydrochlorothiazide
(b/hctz); 2) angiotensin-II-antagonists (AIIA); 3) calcium-channel
blockers (CCB); or 4) angiotensin-converting enzyme inhibitors
(ACE) from January-August 2000, were followed up for 1.5
years. The prescriptions at inclusion and the ﬁnal prescriptions
in each subsequent quarter were recorded. Patients who
remained on their initial treatment were classiﬁed as persistent.
The average daily drug costs per patient (ADDC) were calculated
for all four groups at all measurement points based on public
prices in France. RESULTS: A total of 1587 patients were
included. The persistence rate at study end was 68.3% in the
low-dose b/hctz group, followed by the AIIA (57.2%), the CCB
(56.1%) and the ACE group (51.7%). Statistical signiﬁcance was
only reached between the b/hctz group and the ACE group (p <
0.01). Switches in therapy and the initiation of combination
treatments led to a steady increase in ADDC in the CCB, ACE
and b/hctz groups during follow-up (from 0.66€ to 0.90€, 0.76€
to 0.86€ and 0.45€ to 0.60€, respectively). In the AIIA group,
ADDC decreased slightly due to switches in therapy to lower-
priced drugs (1.08€ to 1.03€). Pairwise differences in ADDC
between the b/hctz group and all other groups reached signiﬁ-
cance at all measurement points (p < 0.01). CONCLUSION: Fre-
quent changes in treatment make it difﬁcult to predict the
evolution of daily drug costs in hypertension. In our study, the
ADDC in the b/hctz group were lower than in the three com-
parator groups at inclusion and remained lower after the effect
of treatment changes were taken into account.
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THE THIRD PARTY PAYER PERSPECTIVE IN COMPARISON
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OBJECTIVE: To compare the costs of hypertension in Poland,
measured from the third party payer perspective and the societal
perspective. METHODS: The retrospective analysis of the 9286
patients’ records derived from a scientiﬁc project conducted
among GPs’ in the whole of Poland in the year 2000. The time
horizon was 12 months. Calculations were made from the third-
party payer perspective including costs of: drug reimbursement,
physicians’ consultations, laboratory, diagnostic tests and hospi-
talisation. The unit costs were obtained from the Polish National
Health Fund. Calculations from the societal perspective were
also made to evaluate patient expenditure on drugs and indirect
costs. RESULTS: Direct medical costs constituted 59% of the
total hypertension costs in Poland (214€ per patient per year),
16% of which represented the cost of pharmacological treat-
ment. Indirect costs (41%) amounted to 148€ per patient per
year. Assuming that 8.5 million Poles suffer from hypertension,
the total societal burden of hypertension could reach 1.53€
billion annually. From the third-party payer perspective, distrib-
ution of the costs was as follows: laboratory and diagnostic tests
21%, hospitalization 31%, physicians’ consultations, 37% and
drugs only 11%, because of an extremely high patient co-
payment rate of 67%. The total, annual third party payer burden
of hypertension amounted to 723€ million (172€ per patient),
which equalled 47.5% of the total societal costs, including indi-
rect costs. Assuming 400,000 new cases of hypertension annu-
ally, total costs related to the incidence of hypertension in Poland
could reach 65.7€ million. CONCLUSION: The costs of hyper-
tension impact on the third party payer and Polish society to the
same extent. High patient co-payment for antihypertensive drugs
and a relatively low reimbursement rate, lead to limited access
to innovative therapies, which may cause a gradual increase in
hypertension costs in Poland in the future.
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OBJECTIVE: To compare the costs of hypertension in the elderly
with the costs in patients under 65 in Poland. METHODS: The
time horizon of the analysis was 12 months and a retrospective
approach was applied. Calculations were made from the societal
perspective. Direct medical costs of pharmacological treatment,
physicians’ consultations, laboratory, diagnostic tests and hospi-
talisation were identiﬁed and calculated. Indirect costs resulting
from productivity loss were also included in the analysis.
Resource utilisation data were derived from a scientiﬁc project
conducted among GPs’ in the whole of Poland in the year 2000.
The unit costs were obtained from the Polish National Health
Fund. RESULTS: The total annual direct medical cost per patient
in the elderly group was 15% higher than in the group of patients
under 65 and was equal to 239€. The distribution of the direct
medical costs in the elderly group was as follows: drugs 25%,
physicians’ consultations 28%, laboratory, diagnostic tests 21%
and hospitalisation 25%. Both physicians’ consultation costs
(68€ per patient per year) and hospitalisation costs (61€ per
patient per year) were higher in elderly group than in younger
patients (45% and 12% respectively). The indirect costs for
elderly patients were about ten times lower than in patients
under 65, which generated the costs of 214€ per patient per year.
CONCLUSION: The direct medical costs were higher in elderly
hypertensive patients. The indirect costs were higher in younger
hypertensive probably due to retirement at 60 for women and
65 for men in Poland. There are no differences between the com-
pared groups in expenditure on drugs and patients’ co-payment.
The trends observed may have a great impact on the total burden
of hypertension, because of the higher incidence of hypertension
in younger people and the aging of the Polish population.
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OBJECTIVE: The 5 major classes of antihypertensive agents are
suitable for the initiation and maintenance of antihypertensive
therapy according to 2003 European Society of Hypertension—
European Society of Cardiology guidelines. The aim of this study
was to compare the cost-effectiveness of these antihypertensive
agents in mild to moderate hypertension in Greece. METHODS:
